Ronald Kern

Make It Plain: Clarity Regarding Obviousness-Type Double Patenting (Podcast)

The Supreme Court Again Declines To Address The Written Description Standard

Juno Therapeutics Requests That The Supreme Court Wait To Make A Decision On Its Written Description Question Until Amgen's Enablement Case Is Resolved

Supreme Court Denies Review Of The Written Description Requirement

Supreme Court To Address What It Means To Have An Enabling Disclosure

Characterization Of Claim Elements As "Conventional" Results In Section 101 Subject Matter Ineligibility

Federal Circuit Holds That Claims Directed To Methods Of Treating Pain In A Renally Impaired Patient Are Patent-Eligible Under Section 101

The Federal Circuit Opens The Door Wider For The Subject Matter Eligibility Of Methods Of Treatment, Compositions And Methods Of Manufacturing

Federal Circuit Holds That Claims Directed To Diagnosing Neurotransmission Or Developmental Disorders Are Invalid For Failing To Recite Patent Eligible Subject Matter

Supreme Court Denies Sequenom's Petition For Certiorari